{"protocolSection": {"identificationModule": {"nctId": "NCT00360698", "orgStudyIdInfo": {"id": "HMR1964A_4002"}, "secondaryIdInfos": [{"id": "EUDRACT # : 2005-002614-38"}], "organization": {"fullName": "Sanofi", "class": "INDUSTRY"}, "briefTitle": "Insulin Glulisine in Type 2 Diabetic Patients", "officialTitle": "Comparison of Two Therapeutic Strategies for Treating Type 2 Diabetic Patients Poorly Controlled With Basal Insulin Associated With Oral Antidiabetic Drugs : 6-month Proof of Concept Study.", "acronym": "Basal Plus"}, "statusModule": {"statusVerifiedDate": "2011-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-07"}, "primaryCompletionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-08-03", "studyFirstSubmitQcDate": "2006-08-04", "studyFirstPostDateStruct": {"date": "2006-08-07", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-08-20", "resultsFirstSubmitQcDate": "2009-10-27", "resultsFirstPostDateStruct": {"date": "2009-12-02", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-08-01", "lastUpdatePostDateStruct": {"date": "2011-08-08", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Trial Transparency Team", "oldOrganization": "sanofi-aventis"}, "leadSponsor": {"name": "Sanofi", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled with basal insulin plus OADs."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 106, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "insulin glulisine+insulin glargine+metformin+glimepiride", "type": "OTHER", "description": "Bolus arm", "interventionNames": ["Drug: Insulin Glargine", "Drug: Glimepiride", "Drug: Insulin Glulisine", "Drug: Metformin"]}, {"label": "insulin glargine+metformin+glimepiride", "type": "OTHER", "description": "Control arm", "interventionNames": ["Drug: Insulin Glargine", "Drug: Glimepiride", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Insulin Glargine", "description": "One daily injection at bedtime", "armGroupLabels": ["insulin glargine+metformin+glimepiride", "insulin glulisine+insulin glargine+metformin+glimepiride"]}, {"type": "DRUG", "name": "Glimepiride", "description": "At same dosage as during the run-in period", "armGroupLabels": ["insulin glargine+metformin+glimepiride", "insulin glulisine+insulin glargine+metformin+glimepiride"]}, {"type": "DRUG", "name": "Insulin Glulisine", "description": "One bolus given before the main meal", "armGroupLabels": ["insulin glulisine+insulin glargine+metformin+glimepiride"]}, {"type": "DRUG", "name": "Metformin", "description": "At same dosage as during the run-in period", "armGroupLabels": ["insulin glargine+metformin+glimepiride", "insulin glulisine+insulin glargine+metformin+glimepiride"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%", "description": "Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \\<7%", "timeFrame": "at the end of treatment (week 24)"}], "secondaryOutcomes": [{"measure": "Glycosylated Haemoglobin (HbA1c) Value", "timeFrame": "at the end of treatment (week 24)"}, {"measure": "Change in Glycosylated Haemoglobin (HbA1c) Value", "timeFrame": "from baseline to the end of treatment (week 24)"}, {"measure": "Daily Mean Plasma Glucose", "timeFrame": "at the end of treatment (week 24)"}, {"measure": "Change in Daily Mean Plasma Glucose", "timeFrame": "from baseline to the end of treatment (week 24)"}, {"measure": "Change in Weight", "timeFrame": "from baseline to the end of treatment (week 24)"}, {"measure": "Daily Dose of Insulin Glargine", "description": "Mean of 3 daily doses reported during the week prior to the final visit", "timeFrame": "at the end of treatment (week 24)"}, {"measure": "Daily Dose of Insulin Glulisine", "description": "Mean of 3 daily doses reported during the week prior to the final visit", "timeFrame": "at the end of treatment (week 24)"}, {"measure": "Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL", "timeFrame": "during treatment period (12 weeks)"}, {"measure": "Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL", "timeFrame": "during treatment period (12 weeks)"}, {"measure": "Rate of Severe Symptomatic Hypoglycemia", "timeFrame": "during treatment period (12 weeks)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diabetes Mellitus, Type 2\n* 25 \\< BMI \\< 45 kg/m\u00b2\n* 7,5% \\< HbA1c \\< 9%\n* Treated with a basal insulin (NPH, Insulin Zinc, Insulin glargine or Insulin detemir), and at least 1g metformin daily, for more than 3 months\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Treatment with OADs only\n* Treatment with thiazolidinediones, with exenatide or with pramlintide\n* Treatment with an insulin other than basal insulin (Premix, rapid insulin, fast-acting insulin analogue)\n* Active proliferative diabetic retinopathy,\n* Pregnancy (women of childbearing potential must have a negative pregnancy test at study entry and effective contraception)\n* Breast-feeding\n* History of hypersensitivity to the study drugs or to drugs with a similar chemical structure.\n* Treatment with systemic corticosteroids in the 3 months prior to study entry\n* Treatment with any investigational product in the 2 months prior to study entry\n* Previous treatment with insulin glulisine\n* Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol\n* Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult\n* Impaired hepatic function\n* Impaired renal function\n* History of drug or alcohol abuse\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "PILORGET Val\u00e9rie, MD", "affiliation": "Sanofi", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Sanofi-aventis", "city": "Bridgewater", "state": "New Jersey", "zip": "08807", "country": "United States", "geoPoint": {"lat": 40.60079, "lon": -74.64815}}, {"facility": "Sanofi-Aventis", "city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Sanofi-aventis", "city": "Guildford", "country": "United Kingdom", "geoPoint": {"lat": 51.23536, "lon": -0.57427}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "During Run-In period patients were not assigned to a treatment group. They were all treated with Insulin Glargine + Metformin + Glimepiride.", "groups": [{"id": "FG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "FG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "periods": [{"title": "Run-In", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "135"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "comment": "19 patients completed the run-in but were not eligible for randomization in the treatment period", "numSubjects": "125"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Non compliance with treatment procedure", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Sponsor request", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Patient did not meet inclusion criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Patient personal reasons", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Need of insulin with meals", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Treatment Period", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "57"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "48"}, {"groupId": "FG001", "numSubjects": "56"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Non compliance with treatment procedure", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Early termination by error", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "BG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "49"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "106"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "60.6", "spread": "6.73"}, {"groupId": "BG001", "value": "59.3", "spread": "8.84"}, {"groupId": "BG002", "value": "59.9", "spread": "7.92"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "64"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "22"}, {"groupId": "BG002", "value": "42"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "27"}, {"groupId": "BG002", "value": "50"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "25"}]}]}, {"title": "Russian Federation", "categories": [{"measurements": [{"groupId": "BG000", "value": "15"}, {"groupId": "BG001", "value": "16"}, {"groupId": "BG002", "value": "31"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "Total patients analyzed n=105 due to one missing data in the \"insulin glulisine+insulin glargine+metformin+glimepiride\" group", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m\u00b2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.2", "spread": "5.30"}, {"groupId": "BG001", "value": "33.3", "spread": "4.39"}, {"groupId": "BG002", "value": "33.3", "spread": "4.80"}]}]}]}, {"title": "Daily Mean Plasma Glucose", "description": "Patients having a baseline value and a value on treatment:\n\ninsulin glulisine+insulin glargine+metformin+glimepiride group n=47 patients, insulin glargine+metformin+glimepiride group n=55 patients", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "170.2", "spread": "27.86"}, {"groupId": "BG001", "value": "167.4", "spread": "39.41"}, {"groupId": "BG002", "value": "169", "spread": "34.33"}]}]}]}, {"title": "Duration of diabetes", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12.1", "spread": "7.29"}, {"groupId": "BG001", "value": "11.0", "spread": "7.02"}, {"groupId": "BG002", "value": "11.5", "spread": "7.13"}]}]}]}, {"title": "Glycosylated Haemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percent", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.8", "spread": "0.60"}, {"groupId": "BG001", "value": "8.0", "spread": "0.67"}, {"groupId": "BG002", "value": "7.9", "spread": "0.64"}]}]}]}, {"title": "Weight", "description": "Total patients analyzed n=105 due to one missing data in the \"insulin glulisine+insulin glargine+metformin+glimepiride\" group", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "91.5", "spread": "16.60"}, {"groupId": "BG001", "value": "92.9", "spread": "17.15"}, {"groupId": "BG002", "value": "92.3", "spread": "16.83"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Patients With Glycosylated Haemoglobin (HbA1c) Value < 7%", "description": "Glycosylated Haemoglobin (HbA1c) is a biological parameter that reflects the blood glucose concentration over a long period of time. It is the standard parameter for glycemic control follow -up in diabetic patients. this parameter is expressed in percentage (%) and the target in diabetes management is to reach a HbA1c \\<7%", "populationDescription": "Modified Intent to treat (ITT) population, LOCF (Last Observation Carried Forward)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "at the end of treatment (week 24)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "22.4"}, {"groupId": "OG001", "value": "8.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null-hypothesis stated no differences between the 2 treatment groups regarding the percentage of patients with Glycosylated Haemoglobin (HbA1c) level \\<7%. A sample size of 98 randomized (49/arm) patients would allow to demonstrate with 80% power that 40 % of patients in the Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group would achieve a HbA1c level \\< 7 % compared to 15 % of patients in the Insulin Glargine+Metformin+Glimepiride group(5% alpha risk, 2-sided test).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0499", "statisticalMethod": "Chi-squared", "paramType": "Risk Difference (RD)", "paramValue": "13.68", "ciPctValue": "95", "ciLowerLimit": "0.01", "ciUpperLimit": "28.37", "estimateComment": "Difference in percentage between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group"}]}, {"type": "SECONDARY", "title": "Glycosylated Haemoglobin (HbA1c) Value", "populationDescription": "Modified ITT population, LOCF", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent", "timeFrame": "at the end of treatment (week 24)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.5", "spread": "0.64"}, {"groupId": "OG001", "value": "7.8", "spread": "0.85"}]}]}]}, {"type": "SECONDARY", "title": "Change in Glycosylated Haemoglobin (HbA1c) Value", "populationDescription": "Modified ITT population, LOCF", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "from baseline to the end of treatment (week 24)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.37", "spread": "0.085"}, {"groupId": "OG001", "value": "-0.11", "spread": "0.078"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null-hypothesis stated no difference between the 2 treatment groups regarding the adjusted mean change from baseline in Glycosylated Haemoglobin (HbA1c) at the end of treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.029", "pValueComment": "Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test", "statisticalMethod": "ANCOVA", "statisticalComment": "The analysis is an ANCOVA analysis on the change with group as fixed effect and baseline HbA1c as covariate", "paramType": "Mean Difference (Net)", "paramValue": "-0.26", "ciPctValue": "95", "ciLowerLimit": "-0.49", "ciUpperLimit": "-0.03", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.116", "estimateComment": "Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group"}]}, {"type": "SECONDARY", "title": "Daily Mean Plasma Glucose", "populationDescription": "Modified ITT population, LOCF", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "at the end of treatment (week 24)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "154.7", "spread": "28.62"}, {"groupId": "OG001", "value": "165.8", "spread": "37.48"}]}]}]}, {"type": "SECONDARY", "title": "Change in Daily Mean Plasma Glucose", "populationDescription": "Modified ITT population, LOCF", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "from baseline to the end of treatment (week 24)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "47"}, {"groupId": "OG001", "value": "55"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.01", "spread": "3.661"}, {"groupId": "OG001", "value": "-2.07", "spread": "3.384"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null-hypothesis stated no differences between the 2 treatment groups regarding the adjusted mean change from baseline in daily mean plasma glucose at the end of treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0109", "pValueComment": "Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test", "statisticalMethod": "ANCOVA", "statisticalComment": "The analysis is an ANCOVA analysis on the change with group as fixed effect and baseline daily mean plasma glucose as covariate", "paramType": "Mean Difference (Net)", "paramValue": "-12.94", "ciPctValue": "95", "ciLowerLimit": "-22.83", "ciUpperLimit": "-3.04", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "4.987", "estimateComment": "Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group"}]}, {"type": "SECONDARY", "title": "Change in Weight", "populationDescription": "Modified ITT population, LOCF", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "kg", "timeFrame": "from baseline to the end of treatment (week 24)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "48"}, {"groupId": "OG001", "value": "56"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.46", "spread": "0.316"}, {"groupId": "OG001", "value": "0.22", "spread": "0.293"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null-hypothesis stated no differences between the 2 treatment groups regarding the adjusted mean change from baseline in weight at the end of treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5762", "pValueComment": "Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test", "statisticalMethod": "ANCOVA", "statisticalComment": "The analysis is an ANCOVA analysis on the change with group as fixed effect and baseline weight as covariate", "paramType": "Mean Difference (Net)", "paramValue": "0.24", "ciPctValue": "95", "ciLowerLimit": "-0.61", "ciUpperLimit": "1.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.431", "estimateComment": "Difference between groups: Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride group - Insulin Glargine+Metformin+Glimepiride group"}]}, {"type": "SECONDARY", "title": "Daily Dose of Insulin Glargine", "description": "Mean of 3 daily doses reported during the week prior to the final visit", "populationDescription": "Modified ITT population, LOCF", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units of insulin glargine per day", "timeFrame": "at the end of treatment (week 24)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.7", "spread": "34.84"}, {"groupId": "OG001", "value": "62.2", "spread": "34.85"}]}]}]}, {"type": "SECONDARY", "title": "Daily Dose of Insulin Glulisine", "description": "Mean of 3 daily doses reported during the week prior to the final visit", "populationDescription": "Modified ITT population, LOCF", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units of insulin glulisine per day", "timeFrame": "at the end of treatment (week 24)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "12.8", "spread": "6.59"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL", "populationDescription": "Safety population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of hypoglycemia per patient-year", "timeFrame": "during treatment period (12 weeks)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.19", "spread": "14.603"}, {"groupId": "OG001", "value": "7.68", "spread": "13.996"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null-hypothesis stated no difference between the 2 treatment groups regarding the rate of symptomatic hypoglycemia with plasma glucose \\<70 mg/dL during the treatment period.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.958", "pValueComment": "Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Rate of Nocturnal Symptomatic Hypoglycemia With Plasma Glucose < 70mg/dL", "populationDescription": "Safety population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of hypoglycemia per patient-year", "timeFrame": "during treatment period (12 weeks)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.62", "spread": "3.418"}, {"groupId": "OG001", "value": "3.95", "spread": "9.339"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null-hypothesis stated no difference between the 2 treatment groups regarding the rate of nocturnal symptomatic hypoglycemia with plasma glucose \\<70 mg/dL during the treatment period.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.302", "pValueComment": "Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Rate of Severe Symptomatic Hypoglycemia", "populationDescription": "Safety population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Number of hypoglycemia per patient-year", "timeFrame": "during treatment period (12 weeks)", "groups": [{"id": "OG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}, {"id": "OG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "49"}, {"groupId": "OG001", "value": "57"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.000"}, {"groupId": "OG001", "value": "0.20", "spread": "1.096"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "The null-hypothesis stated no difference between the 2 treatment groups regarding the rate of severe symptomatic hypoglycemia during the treatment period.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.192", "pValueComment": "Threshold for statistical significance (alpha) = 0.05 ; 2 sided-test", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Insulin Glulisine+Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glulisine (One daily injection at main meal) + Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)", "seriousNumAffected": 1, "seriousNumAtRisk": 49, "otherNumAffected": 0, "otherNumAtRisk": 49}, {"id": "EG001", "title": "Insulin Glargine+Metformin+Glimepiride", "description": "Insulin Glargine (One daily injection at bedtime) + Metformin (At same dosage as during the run-in period) + Glimepiride (At same dosage as during the run-in period)", "seriousNumAffected": 2, "seriousNumAtRisk": 57, "otherNumAffected": 0, "otherNumAtRisk": 57}], "seriousEvents": [{"term": "Scleroderma", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 8", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 49}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Tendon Disorder", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 8", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 49}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 57}]}, {"term": "Angina Pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 8", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 49}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}]}, {"term": "Atrial Fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 8", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 49}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 57}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If no publication has occurred within 12 months of the completion of the study, the Investigator shall have the right to publish/present independently the results of the study. The Investigator shall provide the Sponsor with a copy of any such presentation/publication for comment at least 30 days before any presentation/submission for publication. If requested by the Sponsor, any presentation/submission shall be delayed up to 90 days, to allow the Sponsor to preserve its proprietary rights."}, "pointOfContact": {"title": "Medical Affairs study director", "organization": "sanofi-aventis", "email": "publicregistryGMA@sanofi-aventis.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Bulgaria"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000069036", "term": "Insulin Glargine"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "C000479079", "term": "Insulin glulisine"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M347", "name": "Insulin Glargine", "asFound": "Interaction", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M256033", "name": "Insulin glulisine", "asFound": "Ease", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}